• Something wrong with this record ?

Visualisation of in vivo protein synthesis during mycobacterial infection through [68Ga]Ga-DOTA-puromycin μPET/MRI

S. Eigner, J. Kleynhans, DR. Beckford Vera, MM. Sathekge, KE. Henke, T. Ebenhan

. 2024 ; 14 (1) : 19250. [pub] 20240820

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24019300

Radiolabelled puromycin analogues will allow the quantification of protein synthesis through nuclear medicine-based imaging. A particularly useful application could be the non-invasive longitudinal visualisation of mycobacterial activity through direct quantification of puromycin binding. This study assesses the value of [68Ga]Ga-DOTA-puromycin in the visualisation of mycobacteria through positron emission tomography combined with magnetic resonance imaging (μPET/MRI). The radiopharmaceutical was produced by previously published and validated methods. [68Ga]Ga-DOTA-Puromycin imaging was performed on severe immunodeficient mice infected with Bacille Calmette-Guérin-derived M. Bovis (BCG). Acute and chronic infection stages were examined by μPET/MRI. A follow-up group of animals acted as controls (animals bearing S. aureus-derived infection and sterile inflammation) to assess tracer selectivity. [68Ga]Ga-DOTA-puromycin-μPET/MRI images revealed the acute, widespread infection within the right upper shoulder and armpit. Also, [68Ga]Ga-DOTA-puromycin signal sensitivity measured after a 12-week period was lower than that of [18F]FDG-PET in the same animals. A suitable correlation between normalised uptake values (NUV) and gold standard histopathological analysis confirms accurate tracer accumulation in viable bacteria. The radiopharmaceutical showed infection selectivity over inflammation but accumulated in both M. Bovis and S. Aureus, lacking pathogen specificity. Overall, [68Ga]Ga-DOTA-puromycin exhibits potential as a tool for non-invasive protein synthesis visualization, albeit without pathogen selectivity.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019300
003      
CZ-PrNML
005      
20241024111517.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-024-70200-4 $2 doi
035    __
$a (PubMed)39164329
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Eigner, Sebastian $u Department of Radiopharmaceuticals, Nuclear Physics Institute of the Academy of Sciences of the Czech Republic, Husinec-Rez 130, 25068, Husinec-Rez, Czech Republic $u Department of Radiopharmacy, Charles University Prague, 11000, Prague, Czech Republic
245    10
$a Visualisation of in vivo protein synthesis during mycobacterial infection through [68Ga]Ga-DOTA-puromycin μPET/MRI / $c S. Eigner, J. Kleynhans, DR. Beckford Vera, MM. Sathekge, KE. Henke, T. Ebenhan
520    9_
$a Radiolabelled puromycin analogues will allow the quantification of protein synthesis through nuclear medicine-based imaging. A particularly useful application could be the non-invasive longitudinal visualisation of mycobacterial activity through direct quantification of puromycin binding. This study assesses the value of [68Ga]Ga-DOTA-puromycin in the visualisation of mycobacteria through positron emission tomography combined with magnetic resonance imaging (μPET/MRI). The radiopharmaceutical was produced by previously published and validated methods. [68Ga]Ga-DOTA-Puromycin imaging was performed on severe immunodeficient mice infected with Bacille Calmette-Guérin-derived M. Bovis (BCG). Acute and chronic infection stages were examined by μPET/MRI. A follow-up group of animals acted as controls (animals bearing S. aureus-derived infection and sterile inflammation) to assess tracer selectivity. [68Ga]Ga-DOTA-puromycin-μPET/MRI images revealed the acute, widespread infection within the right upper shoulder and armpit. Also, [68Ga]Ga-DOTA-puromycin signal sensitivity measured after a 12-week period was lower than that of [18F]FDG-PET in the same animals. A suitable correlation between normalised uptake values (NUV) and gold standard histopathological analysis confirms accurate tracer accumulation in viable bacteria. The radiopharmaceutical showed infection selectivity over inflammation but accumulated in both M. Bovis and S. Aureus, lacking pathogen specificity. Overall, [68Ga]Ga-DOTA-puromycin exhibits potential as a tool for non-invasive protein synthesis visualization, albeit without pathogen selectivity.
650    _2
$a zvířata $7 D000818
650    12
$a magnetická rezonanční tomografie $x metody $7 D008279
650    12
$a pozitronová emisní tomografie $x metody $7 D049268
650    _2
$a myši $7 D051379
650    12
$a radioizotopy galia $7 D005710
650    12
$a Mycobacterium bovis $7 D009163
650    12
$a radiofarmaka $x chemie $7 D019275
650    _2
$a organokovové sloučeniny $7 D009942
650    _2
$a heterocyklické sloučeniny monocyklické $x chemie $7 D006573
650    _2
$a myši SCID $7 D016513
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a tuberkulóza $x diagnostické zobrazování $x mikrobiologie $x metabolismus $7 D014376
650    _2
$a mykobakteriózy $x diagnostické zobrazování $x mikrobiologie $7 D009164
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kleynhans, Janke $u Nuclear Medicine Research Infrastructure NPC, Pretoria, 0001, South Africa
700    1_
$a Beckford Vera, Dennis R $u Department of Radiopharmaceuticals, Nuclear Physics Institute of the Academy of Sciences of the Czech Republic, Husinec-Rez 130, 25068, Husinec-Rez, Czech Republic
700    1_
$a Sathekge, Mike M $u Nuclear Medicine Research Infrastructure NPC, Pretoria, 0001, South Africa $u Department of Nuclear Medicine, University of Pretoria, Pretoria, 0001, South Africa
700    1_
$a Henke, Katerina Eigner $u Department of Radiopharmacy, Charles University Prague, 11000, Prague, Czech Republic $u Clinical for Nuclear Medicine, University Hospital RWTH Aachen, 52074, Aachen, Germany
700    1_
$a Ebenhan, Thomas $u Nuclear Medicine Research Infrastructure NPC, Pretoria, 0001, South Africa. thomas.ebenhan@up.ac.za $u Department of Nuclear Medicine, University of Pretoria, Pretoria, 0001, South Africa. thomas.ebenhan@up.ac.za
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 14, č. 1 (2024), s. 19250
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39164329 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111511 $b ABA008
999    __
$a ok $b bmc $g 2201873 $s 1231273
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 14 $c 1 $d 19250 $e 20240820 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options